Pfizer Inc. (PFE) is a multinational pharmaceutical and biotechnology company. We research, develop and manufacture biopharmacy in various fields such as oncology, cardiovascular disease, inflammatory disease, immunology, rare disease and vaccine. In collaboration with Germany-based biotechnology company BioNTechSE (BNTX), Pfizer has developed an mRNA-based vaccine against COVID-19. The Pfizer-BioNTech vaccine has been given to millions of people in the United States and abroad, and sales have increased further as the United States and other countries administer booster shots to further protect people from the virus. There is likely to be.
Pfizer’s top shareholders are Frank A. Damerio, John Douglas Young, Michael Dorsten, Vanguard Group Inc., BlackRock Inc. (BLK) and State Street Corporation (STT).
On August 23, 2021, the US Food and Drug Administration (FDA) approved the Pfizer-BioNTech COVID-19 vaccine, which is currently marketed as Comirnaty. Previously, vaccines were only approved under an Emergency Use Authorization (EUA). This was the first vaccine against COVID-19 that was fully approved by the FDA. Vaccines will continue to be available under the EUA, including individuals between the ages of 12 and 15.
Pfizer’s 12-month trailing net income and revenue are $ 13.2 billion and $ 51.6 billion, respectively. The company has a market capitalization of approximately $ 248.4 billion. These financial data are current as of September 16, 2021.
“Insider” refers to senior management and members of the Board of Directors, as well as people or organizations that own 10% or more of the company’s shares. In this context, it has nothing to do with insider trading.
Shares owned by individual insider shareholders are shares held directly. The shares listed in this section do not include shares that are held indirectly or that are accessible through stock options. Company insiders are required to submit SEC Form 4 each time they buy or sell shares in a company that they consider important.
Frank A. Damillion
Frank A. Damerio owns a total of 483,188 shares of Pfizer, which is 0.01% of the company’s total outstanding shares. Damillion is Chief Financial Officer and Executive Vice President of Global Supply. He oversees the company’s corporate finance functions such as auditing, finance, taxation, insurance, business finance and analytics. D’amelio led Pfizer’s acquisition of Wyeth Pharmaceuticals, King Pharmaceuticals, Hospira Inc., Anacor Pharmaceuticals Inc., and Medivation Inc. He also led the spin-off of Zoetis, the company’s veterinary drug business, and its sale. Nutrition business. Prior to joining Pfizer in 2007, Damillion worked at Alcatel-Lucent as Chief Administrative Officer and Senior Vice President of Integration.
John Douglas Young
John Douglas Young owns a total of 461,761 shares of Pfizer, which is 0.01% of the company’s total outstanding shares. Young has been with Pfizer for over 30 years and is the company’s group president and chief executive officer. Prior to his current position, he was Group President of Pfizer Innovative Health. Pfizer Innovative Health included six independent business units focused on developing innovative medicines and vaccines. Young was also responsible for expanding Pfizer’s footsteps in emerging markets in Latin America, Asia, Africa, and the Middle East. Prior to that, he was Group President of Pfizer Essential Health. Young is also a member of the board of directors of the Consumer Healthcare joint venture with GlaxoSmithKline PLC (GSK) and a board member of Johnson Controls International PLC (JCI).
Mikael Dolsten owns a total of 137,727 shares of Pfizer, which is less than 0.01% of the company’s total outstanding shares. Dorsten is Pfizer’s Chief Scientific Officer and President of Global Research and Development Medicine (WRDM). His focus is on the development of scientific advances in small molecule medicines, biotherapy, gene therapy, and vaccines. As President of WRDM, Dorsten oversees all of Pfizer’s research units, including the Center for Oncology, Internal Medicine, Inflammation and Immunology, Vaccines, Rare Diseases, and Therapeutic Innovation. Prior to joining Pfizer in 2009, he was President of Weiss Research and prior to that, he was Executive Vice President and Head of Worldwide Research at Boehringer Ingelheim. Dorsten is the inventor of several patents and has published about 150 articles in international journals.
Top 3 Institutional Investors
Institutional investors own 65-66% of Pfizer’s total outstanding shares.
Vanguard Group Co., Ltd.
The Vanguard Group owns 456.2 million Pfizer shares, which is 8.1% of the total number of issued shares, according to the company’s 13th floor Pfizer for the period ending June 30, 2021. The company is primarily an investment trust and ETF management company with approximately $ 7.2 trillion in Global Assets Under Management (AUM). The Vanguard S & P 500 ETF (VOO) is one of the company’s largest exchange-traded funds (ETFs) with an AUM of approximately $ 256 billion. Pfizer accounts for almost 0.7% of VOO’s stake.
BlackRock Co., Ltd.
BlackRock owns 407 million shares of Pfizer, or 7.3% of the total number of issued shares, according to the company’s 13th floor filing for the period ending June 30, 2021. The company is primarily an investment trust and ETF management company with an AUM of approximately $ 8.7 trillion. The iShares Core S & P 500 ETF (IVV) is one of BlackRock’s largest ETFs, with an AUM of approximately $ 305 billion. Pfizer accounts for almost 0.7% of IVV’s stake.
State Street Corporation.
State Street owns 278.6 million shares of Pfizer, which is 5.0% of the total number of issued shares, according to Pfizer on the 13th floor of the company for the period ending June 30, 2021. The company is primarily a manager of investment trusts, ETFs and other assets, with an AUM of approximately $ 3.9 trillion. The SPDR S & P 500 ETF Trust (SPY) is one of State Street’s largest ETFs, with an AUM of approximately $ 410 billion. Pfizer accounts for almost 0.7% of SPY’s stake.